<h1 id="malignant-hyperpyrexia-malignant-hyperthermia">Malignant hyperpyrexia (malignant hyperthermia)</h1>

<p><strong>Malignant hyperpyrexia (malignant hyperthermia)</strong> Genetic
susceptibility 1 in 5000 to 1 in 10000, usually autosomal dominant.
Complicates 1 in xxx anaesthetics. Susceptible individuals have on
average had 3 uneventful GAs before diagnosis. Precipitants: volatile
agents, suxamethonium, caffeine, emotional stress. Pathophysiology: loss
of skeletal muscle Ca <sup>++</sup> homeostasis; ryanodine receptor
defect xxx</p>

<p>Management:</p>

<p><em>Diagnose:</em></p>

<p>- Masseter spasm (may be only manifestation)</p>

<p>- Hypermetabolic state:</p>

<p>↑CO<sub>2</sub> ↑HR ↑RR ↑VO<sub>2</sub> ↓ S <sub>P</sub> O<sub>2</sub></p>

<p>- Hyperthermia, sweating</p>

<p>- Unstable BP, arrhythmias.</p>

<p><em>Treat:</em></p>

<ol>
  <li>
    <p>Get clean circuit, intubate, ventilate 3x normal</p>
  </li>
  <li>
    <p>Give Dantrolene 1-2mg/kg up to 10mg/kg total</p>
  </li>
</ol>

<p>- Decreases Ca++ release from SR.</p>

<ol>
  <li>
    <p>Cooling: cool iv fluid, sponge skin with water</p>
  </li>
  <li>
    <p>Ongoing management:</p>
  </li>
  <li>
    <p>ICU management:</p>
  </li>
</ol>

<p>Continue dantrolene for 48hr (prevent retriggering)</p>

<p>Correct hypothermia</p>

<p>Treat pulmonary oedema</p>

<p>Monitor muscle oedema: compartment syndrome</p>

<ol>
  <li>Refer pt. To MH centre, Leeds.</li>
</ol>

<p>[Halsall, P.J. et al. <em>BJA CEPD Reviews</em> <strong>3</strong> , 5-9(2003).]</p>
